For anyone who has spent time hiking wooded trails, camping, or simply walking through tall grass, the fear of a tiny tick causing outsized harm is very real. Lyme disease has quietly become one of the most common infectious diseases in the Northern Hemisphere, and yet, for years, doctors have had no vaccine to offer patients. That may be about to change.
On March 23, 2026, Pfizer and French biotech Valneva announced results from their landmark Phase 3 VALOR trial and the numbers are genuinely encouraging.